Interim data for OncoGenex CPRC drug OGX-427 consistent with previous early results
12:20 EDT 7 Jun 2012 | SCRIP
A second interim report on a Phase II study for the OncoGenex Pharmaceuticals compound OGX-247 in the treatment of chemotherapy-naïve, metastatic, castration-resistant prostate cancer (mCPRC) showed 12-week progression-free survival.....
Original Article: Interim data for OncoGenex CPRC drug OGX-427 consistent with previous early results
More From BioPortfolio on "Interim data for OncoGenex CPRC drug OGX-427 consistent with previous early results"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
